The DOI matches its Crossref record; 152 of the 152 references it cites were found in a registry or an index.
Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy
Abstract
Pseudomonas aeruginosa and Acinetobacter baumannii are major nosocomial pathogens worldwide. Both are intrinsically resistant to many drugs and are able to become resistant to virtually any antimicrobial agent. An increasing prevalence of infections caused by multidrug-resistant (MDR) isolates has been reported in many countries. The resistance mechanisms of P. aeruginosa and A. baumannii include the production of beta-lactamases, efflux pumps, and target-site or outer membrane modifications. Resistance to multiple drugs is usually the result of the combination of different mechanisms in a single isolate or the action of a single potent resistance mechanism. There are many challenges in the treatment of MDR P. aeruginosa and A. baumannii, especially considering the absence of new antimicrobials in the drug-development pipeline. In this review, we present the major resistance mechanisms of P. aeruginosa and A. baumannii, and discuss how they can affect antimicrobial therapy, considering recent clinical, microbiological, pharmacokinetic and pharmacodynamic findings of the main drugs used to treat MDR isolates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B., Scheld, M., Spellberg, B., & Bartlett, J. (2009) · Clinical Infectious Diseases · doi:10.1086/595011 · Cited by 4,958
Extended-Spectrum β-Lactamases: a Clinical Update
Paterson, D. L., & Bonomo, R. A. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.4.657-686.2005 · Cited by 3,491
Acinetobacter baumannii : Emergence of a Successful Pathogen
Peleg, A. Y., Seifert, H., & Paterson, D. L. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00058-07 · Cited by 3,316
Carbapenemases: the Versatile β-Lactamases
Queenan, A. M., & Bush, K. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00001-07 · Cited by 2,499
A functional classification scheme for beta-lactamases and its correlation with molecular structure
Bush, K., Jacoby, G. A., & Medeiros, A. A. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.6.1211 · Cited by 2,475
Jacoby, G. A. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00036-08 · Cited by 2,165
An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii
Dijkshoorn, L., Nemec, A., & Seifert, H. (2007) · Nature Reviews Microbiology · doi:10.1038/nrmicro1789 · Cited by 1,828
Ambler, R. P. (1980) · Philosophical Transactions of the Royal Society of London. B, Biological Sciences · doi:10.1098/rstb.1980.0049 · Cited by 1,823
Multiple Mechanisms of Antimicrobial Resistance in Pseudomonas aeruginosa: Our Worst Nightmare?
Livermore, D. M. (2002) · Clinical Infectious Diseases · doi:10.1086/338782 · Cited by 1,453
Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections
Li, J., Nation, R. L., Turnidge, J. D., Milne, R. W., Coulthard, K., Rayner, C. R., & Paterson, D. L. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70580-1 · Cited by 1,388
Clinically Relevant Chromosomally Encoded Multidrug Resistance Efflux Pumps in Bacteria
Piddock, L. J. V. (2006) · Clinical Microbiology Reviews · doi:10.1128/cmr.19.2.382-402.2006 · Cited by 1,231
Aminoglycosides: Activity and Resistance
Mingeot-Leclercq, M.-P., Glupczynski, Y., & Tulkens, P. M. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.4.727 · Cited by 1,113
Efflux-mediated antimicrobial resistance
Poole, K. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki171 · Cited by 1,082
Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review
Zavascki, A. P., Goldani, L. Z., Li, J., & Nation, R. L. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm357 · Cited by 834
Self-citationComparative Genomics of Multidrug Resistance in Acinetobacter baumannii
Fournier, P.-E., Vallenet, D., Barbe, V., Audic, S., Ogata, H., Poirel, L., Richet, H., Robert, C., Mangenot, S., Abergel, C., et al. (2006) · PLoS Genetics · doi:10.1371/journal.pgen.0020007 · Cited by 812
Pseudomonas aeruginosa – a phenomenon of bacterial resistance
Strateva, T., & Yordanov, D. (2009) · Journal of Medical Microbiology · doi:10.1099/jmm.0.009142-0 · Cited by 803
The role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii
Turton, J. F., Ward, M. E., Woodford, N., Kaufmann, M. E., Pike, R., Livermore, D. M., & Pitt, T. L. (2006) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2006.00195.x · Cited by 751
Mechanisms of Multidrug Resistance in Acinetobacter Species and Pseudomonas aeruginosa
Bonomo, R. A., & Szabo, D. (2006) · Clinical Infectious Diseases · doi:10.1086/504477 · Cited by 741
Masuda, N., Sakagawa, E., Ohya, S., Gotoh, N., Tsujimoto, H., & Nishino, T. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.12.3322-3327.2000 · Cited by 722
Emerging carbapenemases in Gram-negative aerobes
Nordmann, P., & Poirel, L. (2002) · Clinical Microbiology and Infection · doi:10.1046/j.1469-0691.2002.00401.x · Cited by 684
Setting and Revising Antibacterial Susceptibility Breakpoints
Turnidge, J., & Paterson, D. L. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00047-06 · Cited by 578
Magnet, S., Courvalin, P., & Lambert, T. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.12.3375-3380.2001 · Cited by 575
16S Ribosomal RNA Methylation: Emerging Resistance Mechanism against Aminoglycosides
Doi, Y., & Arakawa, Y. (2007) · Clinical Infectious Diseases · doi:10.1086/518605 · Cited by 571
Landman, D., Georgescu, C., Martin, D. A., & Quale, J. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00006-08 · Cited by 565
Efflux pumps as antimicrobial resistance mechanisms
Poole, K. (2007) · Annals of Medicine · doi:10.1080/07853890701195262 · Cited by 562
Heteroresistance to Colistin in Multidrug-Resistant Acinetobacter baumannii
Li, J., Rayner, C. R., Nation, R. L., Owen, R. J., Spelman, D., Tan, K. E., & Liolios, L. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00103-06 · Cited by 548
Microbial Cell Individuality and the Underlying Sources of Heterogeneity
Avery, S. V. (2006) · Nature Reviews Microbiology · doi:10.1038/nrmicro1460 · Cited by 521
The β-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter
Livermore, D. M., & Woodford, N. (2006) · Trends in Microbiology · doi:10.1016/j.tim.2006.07.008 · Cited by 510
Plachouras, D., Karvanen, M., Friberg, L. E., Papadomichelakis, E., Antoniadou, A., Tsangaris, I., Karaiskos, I., Poulakou, G., Kontopidou, F., Armaganidis, A., et al. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01361-08 · Cited by 494
Aminoglycoside Resistance in Pseudomonas aeruginosa
Poole, K. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.479-487.2005 · Cited by 470
Adams, M. D., Nickel, G. C., Bajaksouzian, S., Lavender, H., Murthy, A. R., Jacobs, M. R., & Bonomo, R. A. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00284-09 · Cited by 448
Porins, efflux pumps and multidrug resistance in Acinetobacter baumannii
Vila, J., Martí, S., & Sánchez-Céspedes, J. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl509 · Cited by 436
Marchand, I., Damier-Piolle, L., Courvalin, P., & Lambert, T. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.9.3298-3304.2004 · Cited by 407
Falagas, M. E., Koletsi, P. K., & Bliziotis, I. A. (2006) · Journal of Medical Microbiology · doi:10.1099/jmm.0.46747-0 · Cited by 399
Of Pseudomonas, porins, pumps and carbapenems
Livermore, D. M. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/47.3.247 · Cited by 391
Gales, A. C., Reis, A. O., & Jones, R. N. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.1.183-190.2001 · Cited by 382
Self-citationDamier-Piolle, L., Magnet, S., Brémont, S., Lambert, T., & Courvalin, P. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00732-07 · Cited by 357
Roberts, J. A., Kirkpatrick, C. M. J., Roberts, M. S., Robertson, T. A., Dalley, A. J., & Lipman, J. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp139 · Cited by 347
Paterson, D. L. (2006) · Clinical Infectious Diseases · doi:10.1086/504476 · Cited by 344
Molecular understanding of aminoglycoside action and resistance
Jana, S., & Deb, J. K. (2006) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-005-0279-0 · Cited by 336
Lee, K., Yum, J. H., Yong, D., Lee, H. M., Kim, H. D., Docquier, J.-D., Rossolini, G. M., & Chong, Y. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.11.4485-4491.2005 · Cited by 333
Jacobs, C., Frère, J.-M., & Normark, S. (1997) · Cell · doi:10.1016/s0092-8674(00)81928-5 · Cited by 331
Toleman, M. A. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkf210 · Cited by 327
Function of Pseudomonas Porins in Uptake and Efflux
Hancock, R. E. W., & Brinkman, F. S. L. (2002) · Annual Review of Microbiology · doi:10.1146/annurev.micro.56.012302.160310 · Cited by 319
Carbapenemases: Molecular Diversity and Clinical Consequences
Poirel, L., Pitout, J. D., & Nordmann, P. (2007) · Future Microbiology · doi:10.2217/17460913.2.5.501 · Cited by 309
Gales, A. C., Jones, R. N., & Sader, H. S. (2006) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2005.01351.x · Cited by 302
Self-citationVillegas, M. V., Lolans, K., Correa, A., Kattan, J. N., Lopez, J. A., & Quinn, J. P. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01405-06 · Cited by 293
Falagas, M. E., & Karageorgopoulos, D. E. (2008) · Clinical Infectious Diseases · doi:10.1086/528867 · Cited by 290
Köhler, T., van Delden, C., Curty, L. K., Hamzehpour, M. M., & Pechere, J.-C. (2001) · Journal of Bacteriology · doi:10.1128/jb.183.18.5213-5222.2001 · Cited by 287
Efflux-Mediated Resistance to Tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1
Dean, C. R., Visalli, M. A., Projan, S. J., Sum, P.-E., & Bradford, P. A. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.3.972-978.2003 · Cited by 286
Leibovici, L., Paul, M., Poznanski, O., Drucker, M., Samra, Z., Konigsberger, H., & Pitlik, S. D. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.5.1127 · Cited by 280
Mussi, M. A., Limansky, A. S., & Viale, A. M. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.4.1432-1440.2005 · Cited by 276
Emergence of Resistance to Imipenem During Therapy for Pseudomonas aeruginosa Infections
Quinn, J. P., Dudek, E. J., DiVincenzo, C. A., Lucks, D. A., & Lerner, S. A. (1986) · Journal of Infectious Diseases · doi:10.1093/infdis/154.2.289 · Cited by 276
Cephalosporinase over-expression resulting from insertion of ISAba1 in Acinetobacter baumannii
Héritier, C., Poirel, L., & Nordmann, P. (2006) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2005.01320.x · Cited by 266
Ko, K. S., Suh, J. Y., Kwon, K. T., Jung, S.-I., Park, K.-H., Kang, C. I., Chung, D. R., Peck, K. R., & Song, J.-H. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm305 · Cited by 262
Castanheira, M., Toleman, M. A., Jones, R. N., Schmidt, F. J., & Walsh, T. R. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.12.4654-4661.2004 · Cited by 261
Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii
Peleg, A. Y., Adams, J., & Paterson, D. L. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01198-06 · Cited by 257
Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report
Peleg, A. Y., Potoski, B. A., Rea, R., Adams, J., Sethi, J., Capitano, B., Husain, S., Kwak, E. J., Bhat, S. V., & Paterson, D. L. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl441 · Cited by 248
Gales, A. C. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg416 · Cited by 242
Self-citationWestbrock-Wadman, S., Sherman, D. R., Hickey, M. J., Coulter, S. N., Zhu, Y. Q., Warrener, P., Nguyen, L. Y., Shawar, R. M., Folger, K. R., & Stover, C. K. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.12.2975 · Cited by 242
Ruzin, A., Keeney, D., & Bradford, P. A. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm058 · Cited by 238
Poirel, L., Menuteau, O., Agoli, N., Cattoen, C., & Nordmann, P. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.8.3542-3547.2003 · Cited by 235
The Pharmacodynamics of Aminoglycosides
Lacy, M. K., Nicolau, D. P., Nightingale, & Quintiliani, R. (1998) · Clinical Infectious Diseases · doi:10.1086/514620 · Cited by 231
Weldhagen, G. F., Poirel, L., & Nordmann, P. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.8.2385-2392.2003 · Cited by 231
Shakil, S., Khan, R., Zarrilli, R., & Khan, A. U. (2008) · Journal of Biomedical Science · doi:10.1007/s11373-007-9194-y · Cited by 230
Outer membrane proteins responsible for multiple drug resistance in Pseudomonas aeruginosa
Masuda, N., Sakagawa, E., & Ohya, S. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.3.645 · Cited by 226
Nemec, A. (2004) · Journal of Medical Microbiology · doi:10.1099/jmm.0.45716-0 · Cited by 226
McPhee, J. B., Bains, M., Winsor, G., Lewenza, S., Kwasnicka, A., Brazas, M. D., Brinkman, F. S. L., & Hancock, R. E. W. (2006) · Journal of Bacteriology · doi:10.1128/jb.00053-06 · Cited by 225
Defining an extended-spectrum β-lactamase
Livermore, D. M. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2007.01857.x · Cited by 222
Nicas, T. I., & Hancock, R. E. W. (1980) · Journal of Bacteriology · doi:10.1128/jb.143.2.872-878.1980 · Cited by 221
Booth, I. R. (2002) · International Journal of Food Microbiology · doi:10.1016/s0168-1605(02)00239-8 · Cited by 211
Extended-Spectrum Cephalosporinases in Pseudomonas aeruginosa
Rodríguez-Martínez, J.-M., Poirel, L., & Nordmann, P. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01410-08 · Cited by 211
Macfarlane, E. L. A., Kwasnicka, A., & Hancock, R. E. W. (2000) · Microbiology · doi:10.1099/00221287-146-10-2543 · Cited by 209
Acinetobacter radioresistens as a Silent Source of Carbapenem Resistance for Acinetobacter spp
Poirel, L., Figueiredo, S., Cattoir, V., Carattoli, A., & Nordmann, P. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01304-07 · Cited by 205
Carbapenem Resistance Mechanisms in Pseudomonas aeruginosa Clinical Isolates
Pai, H., Kim, J.-W., Kim, J., Lee, J. H., Choe, K. W., & Gotoh, N. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.2.480-484.2001 · Cited by 205
Pharmacodynamics of Polymyxin B against Pseudomonas aeruginosa
Tam, V. H., Schilling, A. N., Vo, G., Kabbara, S., Kwa, A. L., Wiederhold, N. P., & Lewis, R. E. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3624-3630.2005 · Cited by 204
Girlich, D., Naas, T., & Nordmann, P. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.6.2043-2048.2004 · Cited by 201
Karageorgopoulos, D. E., Kelesidis, T., Kelesidis, I., & Falagas, M. E. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn165 · Cited by 193
OXA β-lactamases in Acinetobacter: the story so far
Brown, S., & Amyes, S. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki425 · Cited by 189
Naas, T., & Nordmann, P. (1999) · PubMed · Cited by 183
Colistin Heteroresistance in Acinetobacter and Its Association with Previous Colistin Therapy
Hawley, J. S., Murray, C. K., & Jorgensen, J. H. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00766-07 · Cited by 183
Sobel, M. L., McKay, G. A., & Poole, K. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.10.3202-3207.2003 · Cited by 179
In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates
Owen, R. J., Li, J., Nation, R. L., & Spelman, D. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl512 · Cited by 176
Yum, J. H. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkf043 · Cited by 163
A review of tigecycline — the first glycylcycline
Peterson, L. R. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(09)70005-6 · Cited by 161
Vidal, L., Gafter-Gvili, A., Borok, S., Fraser, A., Leibovici, L., & Paul, M. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm193 · Cited by 158
Falagas, M. E., Rafailidis, P. I., Matthaiou, D. K., Virtzili, S., Nikita, D., & Michalopoulos, A. S. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2008.05.016 · Cited by 154
Naas, T., & Nordmann, P. (1999) · Current Pharmaceutical Design · doi:10.2174/1381612805666230112185101 · Cited by 154
Piperacillin–tazobactam: a β-lactam/β-lactamase inhibitor combination
Gin, A. S., Dilay, L., Karlowsky, J. A., Walkty, A. J., Rubinstein, E., & Zhanel, G. G. (2007) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.5.3.365 · Cited by 153
Metallo-β-lactamases as emerging resistance determinants in Gram-negative pathogens: open issues
Cornaglia, G., Akova, M., Amicosante, G., Cantón, R., Cauda, R., Docquier, J., Edelstein, M. V., Frère, J., Füzi, M., Galleni, M., et al. (2007) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2006.10.008 · Cited by 151
Gordon, N. C., & Wareham, D. W. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn555 · Cited by 148
Li, X.-Z., Poole, K., & Nikaido, H. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.1.27-33.2003 · Cited by 144
Amin, N. M. E., Giske, C. G., Jalal, S., KEIJSER, B., Kronvall, G., & Wretlind, B. (2005) · Apmis · doi:10.1111/j.1600-0463.2005.apm1130306.x · Cited by 142
Bergen, P. J., Li, J., Nation, R. L., et al. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm511 · Cited by 140
A Step Closer to Extreme Drug Resistance (XDR) in Gram-Negative Bacilli
Paterson, D. L., & Doi, Y. (2007) · Clinical Infectious Diseases · doi:10.1086/522287 · Cited by 139
Tan, C.-H., Li, J., & Nation, R. L. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01571-06 · Cited by 138
Cefepime: a reappraisal in an era of increasing antimicrobial resistance
Endimiani, A., Pérez, F., & Bonomo, R. A. (2008) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.6.6.805 · Cited by 137
Li, J., Rayner, C. R., Nation, R. L., Deans, R., Boots, R. J., Widdecombe, N., Douglas, A., & Lipman, J. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.11.4814-4815.2005 · Cited by 133
Timing and Dynamics of Single Cell Gene Expression in the Arabinose Utilization System
Megerle, J. A., Fritz, G., Gerland, U., Jung, K., & Rädler, J. O. (2008) · Biophysical Journal · doi:10.1529/biophysj.107.127191 · Cited by 132
Spread of blaCTX-M-type and blaPER-2 β-lactamase genes in clinical isolates from Bolivian hospitals
Celenza, G., Pellegrini, C., Caccamo, M., Segatore, B., Amicosante, G., & Perilli, M. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl055 · Cited by 130
Arroyo, L. A. R., García-Curiel, A., Pachón-Ibáñez, M. E., Llanos, A. C., Ruiz, M. T., Pachón, J., & Aznar, J. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.2.903-905.2005 · Cited by 130
Nicasio, A. M., Ariano, R. E., Zelenitsky, S. A., Kim, A., Crandon, J. L., Kuti, J. L., & Nicolau, D. P. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01141-08 · Cited by 123
Higgins, P. G., Wisplinghoff, H., Stefanik, D., & Seifert, H. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh427 · Cited by 120
al Naiemi, N., Duim, B., Savelkoul, P. H. M., et al. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.9.4862-4864.2005 · Cited by 116
Bradford, P. A., Petersen, P. J., Young, M., Jones, C. H., Tischler, M., & O’Connell, J. F. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3903-3909.2005 · Cited by 113
Tanaseanu, C. M., Bergallo, C., Teglia, O., Jasovich, A., Oliva, M. E., Dukart, G., Dartois, N., Cooper, C. A., Gandjini, H., & Mallick, R. (2008) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2008.04.009 · Cited by 112
Bhat, S. V., Peleg, A. Y., Lodise, T. P., Shutt, K. A., Capitano, B., Potoski, B. A., & Paterson, D. L. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01487-06 · Cited by 111
Tam, V. H., Gamez, E. A., Weston, J. S., Gerard, L. N., LaRocco, M., Caeiro, J. P., Gentry, L. O., & Garey, K. W. (2008) · Clinical Infectious Diseases · doi:10.1086/528712 · Cited by 110
Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint
Burkhardt, O., Rauch, K., Kaever, V., Hadem, J., Kielstein, J. T., & Welte, T. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.01.015 · Cited by 106
Russo, T. A., MacDonald, U., Beanan, J. M., Olson, R., MacDonald, I. J., Sauberan, S. L., Luke, N. R., Schultz, L. W., & Umland, T. C. (2009) · The Journal of Infectious Diseases · doi:10.1086/596317 · Cited by 105
Vasilev, K. A., Reshedko, G., Orăsan, R., Sánchez, M., Teras, J., Babinchak, T., Dukart, G., Cooper, A., Dartois, N., Gandjini, H., et al. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn249 · Cited by 102
Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units
Roos, J. F., Bulitta, J. B., Lipman, J., & Kirkpatrick, C. M. J. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl349 · Cited by 101
VIM-1 Metallo-β-lactamase inAcinetobacter baumannii
Tsakris, A., Ikonomidis, A., Pournaras, S., TZOUVELEKIS, L. S., Sofianou, D., Legakis, N. J., & Maniatis, A. N. (2006) · Emerging infectious diseases · doi:10.3201/eid1206.051097 · Cited by 101
Schurek, K. N., Sampaio, J. L. M., Kiffer, C. R. V., Sinto, S. I., Mendes, C. M. F., & Hancock, R. E. W. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01267-08 · Cited by 100
Bergallo, C., Jasovich, A., Teglia, O., Oliva, M. E., Lentnek, A. L., de Wouters, L., Zlocowski, J. C., Dukart, G., Cooper, A., & Mallick, R. (2008) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2008.09.001 · Cited by 94
Huang, L.-Y., Chen, T.-L., Lu, P., Tsai, C.-A., Cho, W.-L., Chang, F. ‐., Fung, C., & Siu, L.-K. K. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2008.02077.x · Cited by 92
Identification of an OprD Homologue in Acinetobacter baumannii
Dupont, M., Pagès, J., Lafitte, D., Siroy, A., & Bollet, C. (2005) · Journal of Proteome Research · doi:10.1021/pr050143q · Cited by 92
Treatment options for multidrug-resistant bacteria
Giamarellou, H. (2006) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.4.4.601 · Cited by 91
Nemec, A., Maixnerová, M., van der Reijden, T. J. K., van den Broek, P. J., & Dijkshoorn, L. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm231 · Cited by 91
Independent emergence of colistin-resistant Acinetobacter spp. isolates from Korea
Park, Y. K., Jung, S.-I., Park, K. H., Cheong, H. S., Peck, K. R., Song, J., & Ko, K. S. (2009) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2009.01.012 · Cited by 82
Zhao, Q., Li, X.-Z., Mistry, A., Srikumar, R., Zhang, L., Lomovskaya, O., & Poole, K. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.9.2225 · Cited by 78
Sulbactam-containing β-lactamase inhibitor combinations
Akova, M. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2007.01847.x · Cited by 73
Farra, A., Islam, S., Strålfors, A., Sörberg, M., & Wretlind, B. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.12.016 · Cited by 73
Castanheira, M., Bell, J. M., Turnidge, J. D., Mathai, D., & Jones, R. N. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01011-08 · Cited by 73
A CTX-M extended-spectrum β-lactamase in Pseudomonas aeruginosa and Stenotrophomonas maltophilia
al Naiemi, N., Duim, B., & Bart, A. (2006) · Journal of Medical Microbiology · doi:10.1099/jmm.0.46704-0 · Cited by 72
Garza–Ramos, U., Morfín‐Otero, R., Sader, H. S., et al. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00679-07 · Cited by 72
The Pseudomonas aeruginosa tonB gene encodes a novel TonB protein
Poole, K., Zhao, Q., Neshat, S., Heinrichs, D. E., & Dean, C. R. (1996) · Microbiology · doi:10.1099/13500872-142-6-1449 · Cited by 69
Touati, A., Brasme, L., Benallaoua, S., Gharout, A., Madoux, J., & de Champs, C. (2007) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2007.10.002 · Cited by 68
Okamoto, K., Gotoh, N., & Nishino, T. (2002) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-002-0193-7 · Cited by 66
Brinkman, F. S. L., Bains, M., & Hancock, R. E. W. (2000) · Journal of Bacteriology · doi:10.1128/jb.182.18.5251-5255.2000 · Cited by 64
A Pseudomonas aeruginosa isolate producing the GES-5 extended-spectrum -lactamase
Wang, C. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl116 · Cited by 63
Sevillano, E., Gallego, L., & Garcı́a-Lobo, J. M. (2008) · Pathologie Biologie · doi:10.1016/j.patbio.2008.05.002 · Cited by 62
Model System To Evaluate the Effect of ampD Mutations on AmpC-Mediated β-Lactam Resistance
Schmidtke, A. J., & Hanson, N. D. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01458-05 · Cited by 62
Combination Antimicrobial Treatment Versus Monotherapy: The Contribution of Meta-analyses
Paul, M., & Leibovici, L. (2009) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2009.01.004 · Cited by 53
Gotoh, N., Tsujimoto, H., Nomura, A., Okamoto, K., Tsuda, M., & Nishino, T. (1998) · FEMS Microbiology Letters · doi:10.1016/s0378-1097(98)00250-x · Cited by 52
What is in the pipeline for Gram-negative pathogens?
Talbot, G. H. (2008) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.6.1.39 · Cited by 51
A pleiotropic, posttherapy, enoxacin-resistant mutant of Pseudomonas aeruginosa
Piddock, L. J. V., Hall, M. C., Bellido, F., Bains, M., & Hancock, R. E. W. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.5.1057 · Cited by 50
Potron, A., Poirel, L., Croizé, J., Chanteperdrix, V., & Nordmann, P. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01164-08 · Cited by 50
Siarkou, V. I., Vitti, D., Protonotariou, E., Ikonomidis, A., & Sofianou, D. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01230-08 · Cited by 49
Casal, M., Rodríguez, F., Johnson, B., et al. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp169 · Cited by 46
IMP-1 and a Novel Metallo-β-Lactamase, VIM-6, in Fluorescent Pseudomonads Isolated in Singapore
Koh, T. H., Wang, G. C. Y., & Sng, L. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.6.2334-2336.2004 · Cited by 43
Petersen, P. J., & Bradford, P. A. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3910-3918.2005 · Cited by 42
The new treatment paradigm and the role of carbapenems
Masterton, R. G. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2008.07.023 · Cited by 41
Sader, H. S., & Jones, R. N. (2005) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2005.01.011 · Cited by 40
Genetic Elements Carrying Macrolide Efflux Genes in Streptococci
Pozzi, G., Iannelli, F., Oggioni, M. R., Santagati, M., & Stefani, S. (2004) · Current Drug Targets - Infectious Disorders · doi:10.2174/1568005043340641 · Cited by 39
Weldhagen, G. F., & Prinsloo, A. (2004) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2003.12.012 · Cited by 31
Ryoo, N. H., Lee, K., Lim, J., Lee, Y. H., Bae, I. K., & Jeong, S. H. (2008) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2008.08.019 · Cited by 30
Jaruratanasirikul, S., & Sudsai, T. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn543 · Cited by 28
Nucleotide Sequence of the bla RTG-2 (CARB-5) Gene and Phylogeny of a New Group of Carbenicillinases
Choury, D., Szajnert, M., Joly‐Guillou, M., Azibi, K., Delpech, M., & Paul, G. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.4.1070-1074.2000 · Cited by 22
Fernández-Cuenca, F., Pascual, Á., Martı́nez-Martı́nez, L., et al. (2003) · Journal of Basic Microbiology · doi:10.1002/jobm.200390022 · Cited by 20
Treatment of Pseudomonas aeruginosa infection in critically ill patients
Grossi, P., & Gasperina, D. D. (2006) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.4.4.639 · Cited by 17
Establishing the role of tigecycline in an era of antimicrobial resistance
Schafer, J. J., & Goff, D. A. (2008) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.6.5.557 · Cited by 15
Cited by
Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria
Nikaido, H., & Pagès, J.-M. (2012) · FEMS Microbiology Reviews · doi:10.1111/j.1574-6976.2011.00290.x · Cited by 769
Fishman, N., Society for Healthcare Epidemiology of America, Infectious Diseases Society of America, & Pediatric Infectious Diseases Society (2012) · Infection Control & Hospital Epidemiology · doi:10.1086/665010 · Cited by 677
Ellington, M. J., Ekelund, O., Aarestrup, F. M., Canton, R., Doumith, M., Giske, C., Grundman, H., Hasman, H., Holden, M. T. G., Hopkins, K. L., et al. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2016.11.012 · Cited by 603
The Surgical Infection Society Revised Guidelines on the Management of Intra-Abdominal Infection
Mazuski, J. E., Tessier, J. M., May, A. K., Sawyer, R. G., Nadler, E. P., Rosengart, M. R., Chang, P. K., O'Neill, P. J., Mollen, K. P., Huston, J. M., et al. (2017) · Surgical Infections · doi:10.1089/sur.2016.261 · Cited by 573
World Health Organization Report: Current Crisis of Antibiotic Resistance
Talebi Bezmin Abadi, A., Rizvanov, A. A., Haertlé, T., & Blatt, N. L. (2019) · BioNanoScience · doi:10.1007/s12668-019-00658-4 · Cited by 465
Metadata
- Authors
- Zavascki, A. P., Carvalhaes, C. G., Picão, R. C., & Gales, A. C.
- Venue
- Expert Review of Anti-infective Therapy
- Publisher
- Informa UK Limited
- Published
- 2010-01
- Volume
- 8
- Issue
- 1
- Pages
- 71-93
- ISSN
- 1478-7210 (ISSN-L)
- 1744-8336
- OpenAlex
- W2152944378
- Cited by
- 312
- References
- 152
- FWCI
- 8.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.